Bli medlem
Bli medlem

Du är här


Redeye: Redeye Initiates Coverage of Enzymatica

Redeye initiates coverage of Enzymatica, a Swedish commercial-stage medtech company offering ColdZyme for treating, alleviating, and shortening the duration of a cold. Its establishment in the Swedish market, followed by an ongoing global expansion with well-known distribution partners, offers a compelling case, where we expect a sales CAGR of 59% between 2022-2026e.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.


Redeye Initiates Coverage of Enzymatica

Författare MFN